Gallium Citrate
drugOn this page
Also known as Citric acid, gallium salt (1:1)NSC-15011
Summary
Gallium Citrate (CHEMBL2110553) is an approved small molecule; indicated across 1 condition including endocarditis.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 1 condition
- Clinical trials: 1
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2110553 |
| Name | Gallium Citrate |
| Type | Small molecule |
| Max phase | 4 |
Also known as: Citric acid, gallium salt (1:1), Gallium citrate, NSC-15011, GALLIUM CITRATE
Parent form; salt/anhydrous children: CHEMBL1200994
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| endocarditis | 2 | MONDO:0005025 | MONDO:0000565 |
Clinical trials
Total trials: 1.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02776891 | PHASE2 | WITHDRAWN | A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor (MYC) Protein Expression in Diffuse Large B-Cell Lymphoma |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.